Bilayered nail lacquer of terbinafine hydrochloride for treatment of onychomycosis

Journal of Pharmaceutical Sciences

Volumn 99, Issue 10, 2010, Pages 4267-4276

  Shivakumar, H N ^a   Vaka, Siva Ram Kiran ^a   Madhav, N V Satheesh ^b   Chandra, Harish ^b   Murthy, S Narasimha ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b DIT UNIVERSITY   (India)

Author keywords

Bilayer; Calorimetry (DSC); Microscopy; Nail; Onychomycosis

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 400; PAINT; TERBINAFINE; VINYL DERIVATIVE;

ARTICLE; CADAVER; CALORIMETRY; COMPOSITE MATERIAL; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; ONYCHOMYCOSIS;

EID: 77957350296     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22150     Document Type: Article

References (32)

1. Gupta A, Scher R. 1998. Oral antifungals agents for onychomycosis. Lancet 351:541-542.
2. Migdley G, Moore MK, Cook JC. 1994. Mycology of nail disorders. J Am Acad Dermatol 31:68-74.
3. Niewerth M, Korting HC. 1999. Management of onychomycosis. Drugs 58:283-296.
4. Roberts DT. 1999. Onychomycosis: Current treatment and future challenges. Br J Dermatol 141:1-4.
5. Murdan S. 2002. Drug delivery to the nail following topical application. Int J Pharm 236:1-26. (Pubitemid 34219369)
6. Baran R. 2000. Dermatology of topical anti-fungal preparations in nail tissue. In: Gabard B, Elsner P, Surber C, Treffel P, editors. Dermatology of topical preparations. London: Springer. pp. 281-295.
7. Hui X, Wester RC, Barbadillo S, Lee C, Patel B, Wortzmman M, Gans EH, Maibach HI. 2004. Ciclopirox delivery into the human nail plate. J Pharm Sci 93:2545-2548. (Pubitemid 39319437)
8. Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF. 2005. In vitro transungal permeation of ciclopirox from a hydroxypropyl chitosan-based, water soluble nail lacquer. Drug Dev Ind Pharm 31:11-17.
9. Hui X, Baker SJ, Wester RC, Barbadillo S, Cashmore AK, Sanders V, Hold KM, Akama T, Zhang Y-K, Plattner JJ, Maibach HI. 2007. In vitro penetration of novel oxaborole antifungal (AN 2690) into the human nail plate. J Pharm Sci 96:2622-2631.
10. Drakes MJM, Scott LJ, Goa KL. 2003. Terbinafine: A review of its use in onychomycosis in adults. Am J Clin Dermatol 4:39-65. (Pubitemid 36082885)
11. Gupta AK, Ryder JE, Lynch LE, Tavakkol A. 2005. The use of terbinafine in the treatment of onychomycosis in adults and special populations: A review of the evidence. J Drug Dermatol 4:302-308.
12. Murthy SN, Wiskerchen DE, Bowers PC. 2007. Iontophoretic drug delivery across human nail. J Pharm Sci 96: 305-311. (Pubitemid 46363561)
13. Repka MA, Mididoddi PK, Stodghill SP. 2004. Influence of human nail etching for the assessment of topical onychomycosis therapies. Int J Pharm 282:95-106.
14. Nair AB, Vaka SRK, Sammeta SM, Kim HD, Friden PM, Chakraborthy B, Murthy SN. 2009. Trans-ungual iontophoretic delivery of terbinafine hydrochloride. J Pharm Sci 98:1788-1796.
15. Pittrof F, Gerhards J, Erni W, Klecak G. 1992. Loceryl1 nail lacquer-realisation of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol 17:26-28.
16. Harwood RJ. 2003. Hypromellose. In: Rowe RC, Sheskey PJ, Weller PJ, editors. Handbook of pharmaceutical excipients. London: Pharmaceutical Press and the American Pharmaceutical Association pp. 297-300.
17. Murthy SN, Vaka SRK, Sammeta SM, Nair AB, TranScreenN™. 2009. Method for rapid screening of trans-ungual drug delivery enhancers. J Pharm Sci 98:4264-4271.
18. United States Pharmacopeial Commission. 2010. The United States Pharmacopeia 33-NF 28. Rockvilli, MD: US Pharmacopeial Convention pp. 4841-4842.
19. Mididoddi PK, Repka MA. 2007. Characterization of hot melt extruded drug delivery system for onychomycosis. Eur J Pharm Biopharm 66: 95-105.
20. Mididoddi PK, Repka MA. 2007. Characterization of hot melt extruded drug delivery system for onychomycosis. Eur J Pharm Biopharm 66:95-105.
21. Mididoddi PK, Prodduturi S, Repka MA. 2006. Influence of tartaric acid on the bioadhesion and mechanical properties of hot melt extruded hydroxypropyl films for the human nail. Drug Dev Ind Pharm 32:1059-1066. (Pubitemid 44521823)
22. Gunt HB, Kasting GB. 2007. Effect of hydration on permeation of ketoconazole through human nail plate in vitro. Eur J Pharm Sci 32:254-260.
23. Khengar RH, Jones SA, Turner RB, Forbes B, Brown MB. 2007. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm Res 24: 2207-2212. (Pubitemid 350064249)
24. Brown MB, Khengar RH, Turner RB, Forbes B, Traynor MJ, Evans CR, Jones SA. 2009. Overcoming the nail barrier: A systematic investigation of ungual chemical penetration enhancement. Int J Pharm 370:61-67.
25. Spruit D. 1972. Effect of nail polish on the hydration of finger nail. Am Cosmet Perf 87:57-58.
26. Murdan S, Hinsu D, Guimier M. 2008. A few aspects of transonychial water loss (TOWL): Inter-individual, and intra-individual, inter-finger, inter-hand and inter-day variabilities, and the influence of nail plate hydration filing and varnish. Eur J Pharm Biopharm 70:684-689.
27. Marty JL. 1995. Amorolfine nail lacquer: A novel formulation. J Eur Acad Dermatol Venereol 4:S17-S21.
28. Seed J, Seed B. 1996. Nail lacquer composition containing polyhydroxystyrene. US patent 005547660A.
29. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. 2005. Treatment options - Development of consensus guidelines. J Eur Acad Dermatol Venereol 19:25-33. (Pubitemid 41726927)
30. Gupta AK, Cooper EA. 2008. Update in antifungal therapy of dermatophytosis. Mycopatholgia 166:353-367.
31. Faergemann J, Zehender H, Denouel J, Millerioux L. 1993. Levels of terbinafine in plasma, stratum corneum, dermisepidermis (without stratum corneum), sebum, hair and nails during and after 250mg terbinafine once per day for four weeks. Acta Derm Venereol 73:305-309. (Pubitemid 23282980)
32. Baran R, Kaoukhov A. 2005. Topical antifungal drugs for treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 19:21-29. (Pubitemid 40268136)